Clinicopathological characteristics of p53 overexpression in endometrial cancers
Corresponding Author
Masaki Inoue
Department of Obstetrics and Gynecology, Osaka University Medical School, 2-2 Yamadaoka Suita, Osaka 565
Department of Obstetrics and Gynecology, Osaka University Medical School, 2-2 Yamadaoka Suita, Osaka 565Search for more papers by this authorAkira Okayama
Department of Medical Science, Shiga University of Medical Science, Shiga, Japan
Search for more papers by this authorMasami Fujita
Department of Obstetrics and Gynecology, Osaka University Medical School, 2-2 Yamadaoka Suita, Osaka 565
Search for more papers by this authorTakayuki Enomoto
Department of Obstetrics and Gynecology, Osaka University Medical School, 2-2 Yamadaoka Suita, Osaka 565
Search for more papers by this authorMasahiro Sakata
Department of Obstetrics and Gynecology, Osaka University Medical School, 2-2 Yamadaoka Suita, Osaka 565
Search for more papers by this authorOsamu Tanizawa
Department of Obstetrics and Gynecology, Osaka University Medical School, 2-2 Yamadaoka Suita, Osaka 565
Search for more papers by this authorCorresponding Author
Hirotsugu Ueshima
Department of Obstetrics and Gynecology, Osaka University Medical School, 2-2 Yamadaoka Suita, Osaka 565
Department of Obstetrics and Gynecology, Osaka University Medical School, 2-2 Yamadaoka Suita, Osaka 565Search for more papers by this authorCorresponding Author
Masaki Inoue
Department of Obstetrics and Gynecology, Osaka University Medical School, 2-2 Yamadaoka Suita, Osaka 565
Department of Obstetrics and Gynecology, Osaka University Medical School, 2-2 Yamadaoka Suita, Osaka 565Search for more papers by this authorAkira Okayama
Department of Medical Science, Shiga University of Medical Science, Shiga, Japan
Search for more papers by this authorMasami Fujita
Department of Obstetrics and Gynecology, Osaka University Medical School, 2-2 Yamadaoka Suita, Osaka 565
Search for more papers by this authorTakayuki Enomoto
Department of Obstetrics and Gynecology, Osaka University Medical School, 2-2 Yamadaoka Suita, Osaka 565
Search for more papers by this authorMasahiro Sakata
Department of Obstetrics and Gynecology, Osaka University Medical School, 2-2 Yamadaoka Suita, Osaka 565
Search for more papers by this authorOsamu Tanizawa
Department of Obstetrics and Gynecology, Osaka University Medical School, 2-2 Yamadaoka Suita, Osaka 565
Search for more papers by this authorCorresponding Author
Hirotsugu Ueshima
Department of Obstetrics and Gynecology, Osaka University Medical School, 2-2 Yamadaoka Suita, Osaka 565
Department of Obstetrics and Gynecology, Osaka University Medical School, 2-2 Yamadaoka Suita, Osaka 565Search for more papers by this authorAbstract
Using immunohistochemical methods, we analyzed the association between nuclear p53 overexpression and various clinico-pathological parameters in patients with endometrial cancers. Formalin-fined and paraffin-embedded tissue sections from 139 cases of endometrial cancer (endometrioid type, 126; serous papillary type, 12; and clear-cell type, 1) were stained with anti-p53 monoclonal antibody (MAb) DO7. Overexpression of p53 was associated with high malignant potential, including extensive muscular invasion, advanced surgical stage, high histological grade, serous papillary type and a personal history of cancer. Lymph-node metastasis was also related to p53 overexpression with marginal significance. Survival curves determined by the Kaplan-Meier method and univariate analysis showed p53 overexpression to be associated with a poor outcome in endometrial cancer patients. However, multivariate analysis using the stepwise Cox proportional-hazard model showed that whereas lymph-node metastasis, a personal history of cancer and muscular invasion were related to poor survival rates, p53 overexpression was not. Consequently, p53 overexpression itself does not appear to be an independent prognostic factor in endometrial cancer, although a still larger sample of patient material would be required to assess this issue definitively. © 1994 Wiley-Liss, Inc.
References
- Allred, D. C., Clark, G. M., Elledge, R., Isola, J., Visakorpi, Holli, K. and Kallioniemi, O.-P., Association of overexpression of tumor-suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J. nat. Cancer Inst., 85, 200–206 (1993).
-
Anonymous,
Announcements. FIGO stages—1988 revision
Gynecol. Oncol.,
35,
125–127
(1989).
10.1016/0090-8258(89)90027-9 Google Scholar
- Brambilla, E., Gazzeri, S., Moro, D., Fromentel, C. C., Gouyer, V., Jacrot, M. and Brambilla, C., Immunohistochemical study of p53 in human lung carcinomas. Amer. J. Pathol., 143, 199–210 (1993).
- Enomoto, T., Fujita, M., Inoue, M., Rice, J. M., NaKajima, R., Tanizawa, O. and Nomura, T., Allerations of the p53 tumor-suppressor gene and its association with activation of the C-K-ras-2 proto-oncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res., 53, 1883–1888 (1993).
- Fearon, E. R., Hamilton, S. R. and Vogelstein, B., Clonal analysis of human colorectal tumors. Science, 238, 193–197 (1987).
-
Finlay, C. A.,
Hinds, P. W.,
Tan, T. H.,
Eliyahu, D.,
Oren, M. and
Levin, A. J.,
Activating mutations for transformation by p53 produce a gene product that forms an hsc 70-p53 complex with an altered half-life.
Mol. Cell Biol.,
7,
531–539
(1988).
10.1128/MCB.8.2.531 Google Scholar
- Inoue, M., Fujita, M., Enomoto, T., Monden, M., Morimoto, H., Shimano, T. and Tanizawa, O., Immunohistochemical detection of p53 in gynecologic tumors. Amer. J. clin. Pathol., (1994). (In press).
- Iwaya, K., Tsuda, H., Hiraide, H., Tamaki, K., Tamakura, S., Fukutomi, T., Mukai, K. and Hirahashi, S., Nuclear p53 immunore-action associated with poor prognosis of breast cancer. Jap. J. Cancer Res., 82, 835–840 (1991).
- Kohler, M. F., Berchuck, A., Davidoff, A. M., Humphrey, P. A., Dodge, R. K., Iglehart, J. D., Soper, J. T., Clarke-Pearson, D. L., Bast, R. C., Jr. and Marks, J. R., Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res., 52, 1622–1627 (1992).
- Marks, J. R., Davidoff, A. M., Kerns, B. J., Humphrey, P. A., Pence, J. C., Dodge, R. K., Clarke-Pearson, D. L., Iglehart, J. D., Bast, R. C. Jr. and Berchuck, A., Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res., 51, 2979–2984 (1991).
- Martin, H. M., Filipe, M. I., Morris, R. W., Lane, D. P. and Silverstre, F., p53 expression and prognosis in gastric carcinoma. Int. J. Cancer, 50, 859–862 (1992).
- McGuire, W. L., Tandon, A. K., Allred, D. C., Chamness, G. C. and Clark, G. M., How to use prognostic factors in axillary node-negative breast cancer patients. J. nat. Cancer Inst., 82, 1006–1015 (1990).
- Milner, B. J., Allan, L. A., Eccles, D. M., Kitchener, H. C., Leonard, R. C. F., Kelly, K. F., Parkin, D. E. and Haites, N. E., p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res., 53, 2128–2132 (1993).
- Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hostetter, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F. S., Weston, A., Modali, R., Harris, C. C. and Vogelstein, B., Mutations in the p53 gene occur in diverse human types. Nature (Lond.), 342, 705–708 (1989).
- Okamoto, A., Samechima, Y., Yamada, Y., Teshima, S., Terashima, Y., Terada, M. and Yokota, J., Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus. Cancer Res., 51, 5632–5636 (1991).
- Quinlan, D. C., Davidson, A. G., Summers, C. L., Warden, H. E. and Doshi, H. M., Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res., 52, 4828–4831 (1992).
- Rodrigues, N. R., Rowan, A., Smith, M. E. F., Kerr, I. B., Bodmer, W. F., Gannon, J. V. and Lane, D. P., p53 mutations in colorectal cancer. Proc. nat. Acad. Sci. (Wash.), 87, 7555–7559 (1990).
- Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Zhang, Z.-F., Sheinfeld, J., Fair, W. R., Herr, H. W. and Reuter, V. E., Nuclear overexpression of p53 protein in transitional-cell bladder carcinoma: a marker for disease progression. J. nat. Cancer Inst., 85, 53–59 (1993).
- Sauter, E. R., Ridge, J. A., Gordon, J. and Eisenberg, B. L., p53 overexpression correlates with increased survival in patients with squamous carcinoma of the tongue base. Amer. J. Surg., 164, 651–653 (1992).
- Scott, N., Stewart, S. J., Blair, G. E., Dixon, M. F. and Quirke, P., p53 in colorectal cancer:clinicopathological correlation and prognostic significance. Brit. J. Cancer, 63, 317–319 (1991).
- Silverberg, S. G. and Kurman, R. J., Tumors of the uterine corpus and gestational trophoblastic disease. Atlas of tumor pathology. Armed Forces Institute of Pathology, Bethesda, MD (1992).
- Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., Levitt, M., Pass, H., Gazdar, A. F. and Minna, J. D., p53: a frequent target for genetic abnormalities in lung cancer. Science, 246, 491–494 (1989).
-
Terakawa, N.,
Inoue, M.,
Shimizu, I.,
Ikegami, H.,
Mizutani, T.,
Sakata, M.,
Tanizawa, O. and
Matsumoto, K.,
Preliminary report on the use of Danazol in the treatment of endometrial adenomatous hyperplasia.
Cancer,
62,
2618–2621
(1988).
10.1002/1097-0142(19881215)62:12<2618::AID-CNCR2820621228>3.0.CO;2-I CAS PubMed Web of Science® Google Scholar
- Thor, A. D., Moore, D. H., II, Edgerton, S. M., Kawasaki, E. S., Reihsaus, E., Lynch, H. T., Marcus, J. N., Schwartz, L., Chen, L.-C., Mayall, B. H. and Smith, H. S., Accumulation of p53 tumor-suppressor gene protein: an independent marker of prognosis in breast cancers. J. nat. Cancer Inst., 84, 845–855 (1992).
- Thor, A. D. and Yandell, D. W., Prognostic significance of p53 overexpression in node-negative breast carcinoma: preliminary studies support cautious optimism. J. nat. Cancer Inst., 85, 176–177 (1993).
- Tsuda, H. and Hirohashi, S., Frequent occurrence of p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histological phenotypes. Jap. J. Cancer Res., 83, 1184–1191 (1992).
- Vojtesek, B., Bartek, J., Midgley, C. A. and Lane, D. P., An immunohistochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J. immunol. Meth., 151, 237–244 (1992).
Citing Literature
